- Conditions
- Breast Cancer
- Interventions
- NeuVax vaccine, Trastuzumab, GM-CSF
- Biological · Drug
- Lead sponsor
- Cancer Insight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 24
- States / cities
- Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 375
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
- Conditions
- Pediatric Cardiac Surgery, Complication of Extracorporeal Circulation
- Interventions
- Tranexamic acid, Epsilon Aminocaproic Acid
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Oak Lawn, Illinois
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Ravulizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Fort Wayne, Indiana • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151 (Zinpentraxin Alfa)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 51 more
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Interventions
- Sym004, Futuximab, Modotuximab
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Ig-E Mediated Food Allergy
- Interventions
- RPT904, Placebo
- Drug · Other
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
- Conditions
- Glioblastoma
- Interventions
- Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- COVID19
- Interventions
- Tranexamic acid, Placebo oral tablet
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Arthritis, Psoriatic
- Interventions
- CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
- Conditions
- Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
- Interventions
- Concizumab
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Augusta, Georgia + 9 more
- Conditions
- Solid Tumor, Breast Cancer, Cancer of Head and Neck
- Interventions
- RO6874281, Trastuzumab, Cetuximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 7 Days and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more
- Conditions
- Neonatal Apnea, Infants
- Interventions
- Caffeine Citrate
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 0 Days to 27 Weeks
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome
- Interventions
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Oakland, California • San Diego, California + 23 more
- Conditions
- ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
- Interventions
- Rapamycin, High dose etoposide and cytarabine (HiVAC)
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Early Breast Cancer
- Interventions
- EG1206A, Perjeta
- Drug
- Lead sponsor
- EirGenix, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cocaine Addiction
- Interventions
- lidocaine following cue-induced craving, lidocaine following neutral stimulus, saline
- Drug
- Lead sponsor
- Bryon Adinoff
- Other
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas